Corbus Pharmaceuticals Holdings, Inc.

Healthcare · Biotechnology · United States

Last price 4.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 81.62M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.